- What is IMVT's revenue?
- Immunovant, Inc. (IMVT)'s most recent annual revenue is $0 for fiscal year 2026 (ended March 31, 2026). The full 10+ year revenue history and quarterly trend are in the Revenue card on this page; analyst forecasts for the next 1–2 fiscal years are in the forward-revenue card below.
- How is IMVT's revenue growing?
- Immunovant, Inc.'s year-over-year revenue growth rate is shown directly on the Revenue card with a 5-year CAGR for context. The growth trajectory varies materially by quarter — the quarterly view on the card shows the recent acceleration or deceleration.
- What is IMVT's gross margin?
- Immunovant, Inc. (IMVT)'s gross / operating / net margins are layered on the Margins cascade chart on this page. Margin direction (expanding vs compressing year-over-year) is one of the strongest signals for the underlying unit economics.
- What is IMVT's net income?
- Immunovant, Inc.'s most recent annual net income — total earnings after all expenses, interest, and taxes — was $-505.6 million for fiscal year 2026 (ended March 31, 2026). Annual + quarterly views, growth rate, GAAP vs non-GAAP, and per-share figures are all in the Net Income card on this page.
- How current is IMVT's income statement data?
- The income-statement figures for Immunovant, Inc. (IMVT) on this page are as of fiscal year 2026 (ended March 31, 2026). New 10-Q (quarterly) and 10-K (annual) filings are typically parsed and reflected here within 48 hours of SEC submission.
